Brensocatib for people aged 12 and over with non-cystic fibrosis bronchiectasis

Brensocatib is currently in clinical development for the treatment on non-cystic fibrosis bronchiectasis in patients aged 12 and older. Bronchiectasis is a lung condition where inflammation from lung infections causes irreversible damage to the lungs which can get worse over time. During bronchiectasis, the airways are wider and become inflamed with thick phlegm (sputum). This means the airways may not clear properly. Too much phlegm can cause bacterial infections, which can lead to chest infections. Chest infections should be treated quickly to stop lung damage. Symptoms of the condition include repeated infections, coughing up excess sputum, chest pain, and shortness of breath. There are currently limited treatment options for non-cystic fibrosis bronchiectasis, with the main treatment being for the frequent infection’s that patients experience.